New drug aims to shield dialysis Patients' brains from 'Fog' and decline
NCT ID NCT07234890
Summary
This study is testing if a new medication called AV-001 can protect the brain from damage that sometimes happens during dialysis treatments. It will involve 60 patients on long-term dialysis, who will receive either the drug or a placebo before three dialysis sessions in one week. Researchers will use brain scans, blood tests, and memory tests to see if AV-001 helps strengthen blood vessels in the brain and reduces inflammation, potentially lowering the risk of thinking problems and stroke.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMODIALYSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
London Health Sciences Centre
London, Ontario, N6A 5W9, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.